BLAINJECTIONINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
AHZANTIVE (aflibercept-mrbb) by Formycon is 12. First approved in 2024.
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AHZANTIVE (aflibercept-mrbb) is a biosimilar fusion protein that acts as a soluble decoy receptor binding VEGF-A and PlGF to inhibit neovascularization and vascular permeability. It is administered intravitreally for retinal diseases including wet AMD, retinal vein occlusion-associated macular edema, and diabetic macular edema. The drug works by blocking endothelial growth factor signaling pathways critical to abnormal blood vessel formation in the eye.
Growth
Early-stage biosimilar in high-value ophthalmology market with moderate competitive pressure; commercial team buildout likely underway.
Mechanism of Action
12.1 Mechanism of Action Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine…
Worked on AHZANTIVE at Formycon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.